Compare AbCellera Biologics Inc (ABCL) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs AstraZeneca plc — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while AstraZeneca plc trades at $158.2 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 83× AbCellera Biologics Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AZN | |
|---|---|---|
Market Cap | $2.99B | $248.14B |
Sector | Health | Health |
52-Week High | $9.76 | $209.48 |
52-Week Low | $2.78 | $147.06 |
Enterprise Value | $2.58B | $275.41B |
Dividend Yield | — | 2.01% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
